[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 294
Citations 0
News From the Food and Drug Administration
March 1, 2016

New Treatment for Liposarcoma

JAMA. 2016;315(9):861. doi:10.1001/jama.2016.1289

The chemotherapy drug eribulin mesylate has received approval for treating liposarcoma that is unresectable or has metastasized (http://1.usa.gov/1ZWmPRo). Marketed as Halaven, the drug is approved for patients previously treated with chemotherapy that contained an anthracycline drug.

“Halaven is the first drug approved for patients with liposarcoma that has demonstrated an improvement in survival time,” Richard Pazdur, MD, of the FDA’s Center for Drug Evaluation and Research, said in a statement.

First Page Preview View Large
First page PDF preview
First page PDF preview